Coram and Lincare notified of early termination of Hart-Scott-Rodino review.DENVER--(BUSINESS WIRE)--May 23, 1995--Coram Healthcare (NYSE NYSE See: New York Stock Exchange :CRH CRH corticotropin-releasing hormone. CRH abbr. corticotropin-releasing hormone CRH corticotropin releasing hormone. ) and Lincare (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :LNCR LNCR Lincare Holdings (stock symbol) LNCR Least Normalized Cost Replacement ) today announced that they had received notice from the U.S. Federal Trade Commission of the early termination of the waiting period in connection with the government's Hart-Scott-Rodino review of the companies' proposed merger, which was announced on April 18, 1995. The transaction, which is subject to the approval of the shareholders of both companies, is expected to close in July, 1995. Lincare, headquartered in Clearwater, Florida, is one of the nation's largest providers of oxygen and other respiratory therapy services to patients in the home. Coram, headquartered in Denver, is a leading provider of alternate site patient care. CONTACT: Coram Healthcare Corporation Larry Watts, 303/672-8728 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion